Premium
Rabeprazole in a one‐week eradication therapy of Helicobacter pylori : Comparison of different dosages
Author(s) -
MARIO FRANCESCO DI,
DAL BÒ NADIA,
ARAGONA GIOVANNI,
MOUSSA ALI M,
IORI VERONICA,
CAVESTRO GIULIA M,
PILOTTO ALBERTO,
LEANDRO GIOACCHINO,
FRANCESCHI MARILISA,
RUGGE MASSIMO,
FRANZÈ Angelo
Publication year - 2003
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1046/j.1440-1746.2003.03035.x
Subject(s) - tolerability , medicine , helicobacter pylori , rabeprazole , gastroenterology , regimen , tinidazole , omeprazole , dose , breath test , urea breath test , clarithromycin , group b , adverse effect , antibiotics , helicobacter pylori infection , metronidazole , microbiology and biotechnology , biology
Aim: Many data regarding omeprazole‐, lanzoprazole‐ and pantoprazole‐based triple therapy for Helicobacter pylori ( H. pylori ) eradication have been reported, but there is few data present regarding rabeprazole (R) . We report the efficacy and tolerability of rabeprazole in different dosages in association with clarithromycin (C)and tinidazole (T) in H. pylori eradication. Design and Methods: Ninety‐four H. pylori ‐positive patients with dyspeptic symptoms were enrolled and randomly allocated to eradication therapy in two different one‐week regimens. In regimen A, 47 patients received R 20 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d, while in regimen B, 47 patients received R 10 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d. Eradication of H. pylori was evaluated by a 13C urea breath test (UBT) two months after the end of the therapy. Results: Four patients (two in each regimen) did not complete treatment. The H. pylori eradication rate was 91.4% in group A compared to 89.3% in group B ( P‐ value not significant). Minor side‐effects were reported in 4.2% of group A and 6.4% of group B patients. Conclusion: Rabeprazole showed good efficacy and tolerability in one‐week H. pylori therapy at 20 mg b.i.d and 10 mg b.i.d, suggesting the use of the lower dosage. © 2003 Blackwell Publishing Asia Pty Ltd